Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and predictive indicator in breast cancer. However, there is paucity of data specifically referred to women diagnosed at a young age across the different disease settings. We investigated the impact of BMI on treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant chemotherapy (CT) followed by surgery.
Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort / D'Aiuto, M., Chirico, A., De Riggi, M.A., Frasci, G., DE LAURENTIIS, M., Di Bonito, M., Vici, P., Pizzuti, L., Sergi, D., Maugeri Saccà, M., Barba, M., Giordano, A.. - In: CANCER BIOLOGY & THERAPY. - ISSN 1555-8576. - 17:5(2016), p. 470-6. [10.1080/15384047.2016.1156265]
Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort
DE LAURENTIIS, MICHELINO;
2016
Abstract
Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and predictive indicator in breast cancer. However, there is paucity of data specifically referred to women diagnosed at a young age across the different disease settings. We investigated the impact of BMI on treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant chemotherapy (CT) followed by surgery.| File | Dimensione | Formato | |
|---|---|---|---|
|
kcbt-17-05-1156265.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
442.06 kB
Formato
Adobe PDF
|
442.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
